405 related articles for article (PubMed ID: 32372943)
1. Glucocerebrosidase Defects as a Major Risk Factor for Parkinson's Disease.
Avenali M; Blandini F; Cerri S
Front Aging Neurosci; 2020; 12():97. PubMed ID: 32372943
[TBL] [Abstract][Full Text] [Related]
2. The relationship between glucocerebrosidase mutations and Parkinson disease.
Migdalska-Richards A; Schapira AH
J Neurochem; 2016 Oct; 139 Suppl 1(Suppl Suppl 1):77-90. PubMed ID: 26860875
[TBL] [Abstract][Full Text] [Related]
3. Activation of β-Glucocerebrosidase Reduces Pathological α-Synuclein and Restores Lysosomal Function in Parkinson's Patient Midbrain Neurons.
Mazzulli JR; Zunke F; Tsunemi T; Toker NJ; Jeon S; Burbulla LF; Patnaik S; Sidransky E; Marugan JJ; Sue CM; Krainc D
J Neurosci; 2016 Jul; 36(29):7693-706. PubMed ID: 27445146
[TBL] [Abstract][Full Text] [Related]
4. Targeting the GBA1 pathway to slow Parkinson disease: Insights into clinical aspects, pathogenic mechanisms and new therapeutic avenues.
Menozzi E; Toffoli M; Schapira AHV
Pharmacol Ther; 2023 Jun; 246():108419. PubMed ID: 37080432
[TBL] [Abstract][Full Text] [Related]
5. Ambroxol-induced rescue of defective glucocerebrosidase is associated with increased LIMP-2 and saposin C levels in GBA1 mutant Parkinson's disease cells.
Ambrosi G; Ghezzi C; Zangaglia R; Levandis G; Pacchetti C; Blandini F
Neurobiol Dis; 2015 Oct; 82():235-242. PubMed ID: 26094596
[TBL] [Abstract][Full Text] [Related]
6. Glucocerebrosidase Mutations and Synucleinopathies. Potential Role of Sterylglucosides and Relevance of Studying Both GBA1 and GBA2 Genes.
Franco R; Sánchez-Arias JA; Navarro G; Lanciego JL
Front Neuroanat; 2018; 12():52. PubMed ID: 30002620
[TBL] [Abstract][Full Text] [Related]
7. Development and biochemical characterization of a mouse model of Parkinson's disease bearing defective glucocerebrosidase activity.
Mus L; Siani F; Giuliano C; Ghezzi C; Cerri S; Blandini F
Neurobiol Dis; 2019 Apr; 124():289-296. PubMed ID: 30521842
[TBL] [Abstract][Full Text] [Related]
8. Decreased glucocerebrosidase activity and substrate accumulation of glycosphingolipids in a novel GBA1 D409V knock-in mouse model.
Polinski NK; Martinez TN; Gorodinsky A; Gareus R; Sasner M; Herberth M; Switzer R; Ahmad SO; Cosden M; Kandebo M; Drolet RE; Buckett PD; Shan W; Chen Y; Pellegrino LJ; Ellsworth GD; Dungan LB; Hirst WD; Clark SW; Dave KD
PLoS One; 2021; 16(6):e0252325. PubMed ID: 34106956
[TBL] [Abstract][Full Text] [Related]
9. Parkinson's disease: acid-glucocerebrosidase activity and alpha-synuclein clearance.
Blanz J; Saftig P
J Neurochem; 2016 Oct; 139 Suppl 1():198-215. PubMed ID: 26860955
[TBL] [Abstract][Full Text] [Related]
10. A novel glucosylceramide synthase inhibitor attenuates alpha synuclein pathology and lysosomal dysfunction in preclinical models of synucleinopathy.
Cosden M; Jinn S; Yao L; Gretzula CA; Kandebo M; Toolan D; Hatcher NG; Ma L; Lemaire W; Adam GC; Burlein C; Minnick C; Flick R; Watt ML; Mulhearn J; Fraley M; Drolet RE; Marcus JN; Smith SM
Neurobiol Dis; 2021 Nov; 159():105507. PubMed ID: 34509608
[TBL] [Abstract][Full Text] [Related]
11. GBA1 mutations: Prospects for exosomal biomarkers in α-synuclein pathologies.
Johnson PH; Weinreb NJ; Cloyd JC; Tuite PJ; Kartha RV
Mol Genet Metab; 2020 Feb; 129(2):35-46. PubMed ID: 31761523
[TBL] [Abstract][Full Text] [Related]
12. Glucocerebrosidase gene therapy prevents α-synucleinopathy of midbrain dopamine neurons.
Rocha EM; Smith GA; Park E; Cao H; Brown E; Hayes MA; Beagan J; McLean JR; Izen SC; Perez-Torres E; Hallett PJ; Isacson O
Neurobiol Dis; 2015 Oct; 82():495-503. PubMed ID: 26392287
[TBL] [Abstract][Full Text] [Related]
13. Enhancing the Activity of Glucocerebrosidase as a Treatment for Parkinson Disease.
Menozzi E; Schapira AHV
CNS Drugs; 2020 Sep; 34(9):915-923. PubMed ID: 32607746
[TBL] [Abstract][Full Text] [Related]
14. Glucocerebrosidase enzyme activity in GBA mutation Parkinson's disease.
Ortega RA; Torres PA; Swan M; Nichols W; Boschung S; Raymond D; Barrett MJ; Johannes BA; Severt L; Shanker V; Hunt AL; Bressman S; Pastores GM; Saunders-Pullman R
J Clin Neurosci; 2016 Jun; 28():185-6. PubMed ID: 26857292
[TBL] [Abstract][Full Text] [Related]
15. A modulator of wild-type glucocerebrosidase improves pathogenic phenotypes in dopaminergic neuronal models of Parkinson's disease.
Burbulla LF; Jeon S; Zheng J; Song P; Silverman RB; Krainc D
Sci Transl Med; 2019 Oct; 11(514):. PubMed ID: 31619543
[TBL] [Abstract][Full Text] [Related]
16. The Exosomal/Total α-Synuclein Ratio in Plasma Is Associated With Glucocerebrosidase Activity and Correlates With Measures of Disease Severity in PD Patients.
Cerri S; Ghezzi C; Sampieri M; Siani F; Avenali M; Dornini G; Zangaglia R; Minafra B; Blandini F
Front Cell Neurosci; 2018; 12():125. PubMed ID: 29867358
[TBL] [Abstract][Full Text] [Related]
17. The neuroinflammatory role of glucocerebrosidase in Parkinson's disease.
Bo RX; Li YY; Zhou TT; Chen NH; Yuan YH
Neuropharmacology; 2022 Apr; 207():108964. PubMed ID: 35065083
[TBL] [Abstract][Full Text] [Related]
18. Sustained Systemic Glucocerebrosidase Inhibition Induces Brain α-Synuclein Aggregation, Microglia and Complement C1q Activation in Mice.
Rocha EM; Smith GA; Park E; Cao H; Graham AR; Brown E; McLean JR; Hayes MA; Beagan J; Izen SC; Perez-Torres E; Hallett PJ; Isacson O
Antioxid Redox Signal; 2015 Aug; 23(6):550-64. PubMed ID: 26094487
[TBL] [Abstract][Full Text] [Related]
19. The lysosomal β-glucocerebrosidase strikes mitochondria: implications for Parkinson's therapeutics.
Rubilar JC; Outeiro TF; Klein AD
Brain; 2024 Mar; ():. PubMed ID: 38437875
[TBL] [Abstract][Full Text] [Related]
20. Glucocerebrosidase activity, cathepsin D and monomeric α-synuclein interactions in a stem cell derived neuronal model of a PD associated GBA1 mutation.
Yang SY; Gegg M; Chau D; Schapira A
Neurobiol Dis; 2020 Feb; 134():104620. PubMed ID: 31634558
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
